This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McCurley, J. M. Articles by Haigney, M. C. Search for Related Content PubMed PubMed Citation Articles by McCurley, J. M. Articles by Haigney, M. C.

Furosemide and the progression of left ventricular dysfunction in experimental heart failure

John M. McCurley, MD^*, Stephen U. Hanlon, MD^*, Shao-kui Wei, MD^*, Erich F. Wedam, MD, Michael Michalski, MD and Mark C. Haigney, MD^*,*

^* Division of Cardiology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
Division of Cardiology, National Naval Medical Center, Bethesda, Maryland, USA
Division of Cardiology, Naval Medical Center, San Diego, California, USA

Manuscript received December 23, 2003; revised manuscript received March 31, 2004, accepted April 20, 2004.

^* Reprint requests and correspondence: Dr. Mark C. Haigney, Division of Cardiology, Uniformed Services University of the Health Sciences, Room A3060, 4301 Jones Bridge Road, Bethesda, Maryland 20814 (Email: mhaigney{at}usuhs.mil).

OBJECTIVES: We tested the hypothesis that furosemide accelerates the progression of left ventricular systolic dysfunction in a tachycardia-induced porcine model of heart failure.

BACKGROUND: Furosemide activates the renin-angiotensin-aldosterone system in patients with congestive heart failure (CHF). Such activation may contribute to CHF progression, but prospective data are lacking.

METHODS: Thirty-two Yorkshire pigs were randomized to furosemide (1 mg/kg intramuscularly daily, mean 16.1 ± 0.9 mg) or placebo. Thereafter, a pacing model of heart failure was utilized to produce systolic dysfunction in both sets of animals (fractional shortening <0.16 by echocardiogram). The goal was to determine if furosemide would accelerate the progression of left ventricular dysfunction in the "treated" group. After sacrifice, sodium-calcium exchanger currents and their responsiveness to isoproterenol were measured during voltage clamp. All investigators were blinded to treatment assignment.

RESULTS: Furosemide shortened the time to left ventricular dysfunction (35.1 ± 5.1 days in placebo versus 21.4 ± 3.2 days for furosemide animals; p = 0.038, log-rank test). By day 14, aldosterone levels were significantly higher in furosemide animals (43.0 ± 11.8 ng/dl vs. 17.6 ± 4.5 ng/dl; p < 0.05). Serum sodium was reduced (133.0 ± 0.9 mmol/l furosemide vs. 135.7 ± 0.8 mmol/l placebo; p < 0.05), but no difference in norepinephrine, potassium, magnesium, creatinine, or urea nitrogen was present. Basal sodium-calcium exchanger currents were significantly increased and isoproterenol responsiveness depressed by furosemide.

CONCLUSIONS: Tachycardic pigs given furosemide had significant acceleration of both contractile and metabolic features of CHF, including left ventricular systolic dysfunction, elevated serum aldosterone levels, and altered calcium handling in a controlled experimental model of heart failure.

Abbreviations and Acronyms   BUN = blood urea nitrogen   CHF = congestive heart failure   NCX = sodium-calcium exchanger   RAAS = renin-angiotensin-aldosterone system   RALES = Randomized Aldactone Evaluation Study   SOLVD = Studies Of Left Ventricular Dysfunction

This article has been cited by other articles:

				S. Bansal, J. Lindenfeld, and R. W. Schrier Sodium Retention in Heart Failure and Cirrhosis: Potential Role of Natriuretic Doses of Mineralocorticoid Antagonist? Circ Heart Fail, July 1, 2009; 2(4): 370 - 376. [Abstract] [Full Text] [PDF]

				G. M. Felker, C. M. O'Connor, E. Braunwald, and for the Heart Failure Clinical Research Network In Loop Diuretics in Acute Decompensated Heart Failure: Necessary? Evil? A Necessary Evil? Circ Heart Fail, January 1, 2009; 2(1): 56 - 62. [Full Text] [PDF]

				R. M. Witteles, D. Kao, D. Christopherson, K. Matsuda, R. H. Vagelos, D. Schreiber, and M. B. Fowler Impact of Nesiritide on Renal Function in Patients With Acute Decompensated Heart Failure and Pre-Existing Renal Dysfunction: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial J. Am. Coll. Cardiol., November 6, 2007; 50(19): 1835 - 1840. [Abstract] [Full Text] [PDF]

				M. R. Costanzo, M. E. Guglin, M. T. Saltzberg, M. L. Jessup, B. A. Bart, J. R. Teerlink, B. E. Jaski, J. C. Fang, E. D. Feller, G. J. Haas, et al. Ultrafiltration Versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure J. Am. Coll. Cardiol., February 13, 2007; 49(6): 675 - 683. [Abstract] [Full Text] [PDF]

				A. Ahmed, A. Husain, T. E. Love, G. Gambassi, L. J. Dell'Italia, G. S. Francis, M. Gheorghiade, R. M. Allman, S. Meleth, and R. C. Bourge Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods Eur. Heart J., June 2, 2006; 27(12): 1431 - 1439. [Abstract] [Full Text] [PDF]

				R. W. Schrier Role of Diminished Renal Function in Cardiovascular Mortality: Marker or Pathogenetic Factor? J. Am. Coll. Cardiol., January 3, 2006; 47(1): 1 - 8. [Abstract] [Full Text]

				S. R. Goldsmith and M. Gheorghiade Vasopressin Antagonism in Heart Failure J. Am. Coll. Cardiol., November 15, 2005; 46(10): 1785 - 1791. [Abstract] [Full Text] [PDF]

				J. Yoshida, K. Yamamoto, T. Mano, Y. Sakata, M. Nishio, T. Ohtani, M. Hori, T. Miwa, and T. Masuyama Different effects of long- and short-acting loop diuretics on survival rate in Dahl high-salt heart failure model rats Cardiovasc Res, October 1, 2005; 68(1): 118 - 127. [Abstract] [Full Text] [PDF]